LONDON—Strikingly successful treatment results were reported in patients with myelofibrosis — a disabling, disfiguring and fatal cancer, for which no therapy has been available up to now — at the European Haematology Association annual meeting held in London (June 8-12, 2011). Srdan Verstovsek from the MD Anderson Cancer Center in Texas tells ecancer radio about his group’s data from a placebo-controlled study investigating treatment with the monoclonal antibody ruxolitinib which inhibits the JAK II enzyme. Organomegaly was reversed and symptoms reduced in the COMFORT I and COMFORT II studies.
More news from the EHA congress at http://www.ecancermedicalscience.com.
LISTEN
[audio:https://www.audiomedica.com/podcasting/ecancer/110613SrdanVerstovsekPODCASTLoRes.mp3]
Our 3,000 subscribers to mpdsupport.org or bit.ly/joinmpdsupport, have been waiting decades for this dramatic news. Ruxolitinib will likely be the very first JAK2 to receive FDA approval with more JAK2’s to follow. Bless you Dr. Verstovsec.